Daiwa Securities Group
KRYS icon

Daiwa Securities Group’s Krystal Biotech KRYS Stock Holding History

Daiwa Securities Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-86
Closed -$21K – 1323
2025
Q4 		$21K Sell
86
-5
-5% -$1.05K ﹤0.01% 1156
2025
Q3 		$16K Sell
91
-13
-13% -$1.95K ﹤0.01% 1141
2025
Q2 		$14K Buy
104
+9
+9% +$1.32K ﹤0.01% 1108
2025
Q1 		$17K Hold
95
– – ﹤0.01% 1075
2024
Q4 		$15K Sell
95
-10
-10% -$1.77K ﹤0.01% 1096
2024
Q3 		$19K Hold
105
– – ﹤0.01% 1100
2024
Q2 		$19K Hold
105
– – ﹤0.01% 1134
2024
Q1 		$19K Sell
105
-10
-9% -$1.39K ﹤0.01% 1140
2023
Q4 		$14K Buy
115
+19
+20% +$2.11K ﹤0.01% 1149
2023
Q3 		$11K Hold
96
– – ﹤0.01% 1123
2023
Q2 		$11K Hold
96
– – ﹤0.01% 1136
2023
Q1 		$8K Hold
96
– – ﹤0.01% 1123
2022
Q4 		$8K Hold
96
– – ﹤0.01% 1125
2022
Q3 		$7K Hold
96
– – ﹤0.01% 1145
2022
Q2 		$6K Buy
96
+20
+26% +$1.24K ﹤0.01% 1159
2022
Q1 		$5K Hold
76
– – ﹤0.01% 1175
2021
Q4 		$5K Hold
76
– – ﹤0.01% 1198
2021
Q3 		$4K Buy
76
+33
+77% +$1.95K ﹤0.01% 1194
2021
Q2 		$3K Hold
43
– – ﹤0.01% 1110
2021
Q1 		$3K Buy
43
+6
+16% +$436 ﹤0.01% 1110
2020
Q4 		$2K Buy
+37
New +$1.85K ﹤0.01% 1126

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Daiwa Securities Group's KRYS Position: Q1 2026 in Review

Daiwa Securities Group sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 86 shares — an estimated $21K sold.

Daiwa Securities Group first reported a position in KRYS in Q4 2020 and held it in 21 quarters. The position peaked at $21K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Daiwa Securities Group reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 86 Krystal Biotech shares in Q1 2026, an estimated $21K.
  • Daiwa Securities Group first reported a position in Krystal Biotech in Q4 2020 and held it in 21 quarters.
  • Daiwa Securities Group's Krystal Biotech position peaked at $21K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.